Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TG103 in Healthy Chinese Adults
NCT03990090Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GX-G6 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug at Day 28. Started Jul 2019; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03990090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990090.